Fiche du document
4 mai 2021
- doi: 10.3390/vaccines9050454
- issn: 2076-393X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines9050454
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34064410
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2076-393X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A19532FDD59E5
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Thymus-dependent lymphocytes Thymus-derived cells T lymphocytes Thymus-dependent cells Therapeutic immunology Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
M. Saillard et al., « Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. », Serveur académique Lausannois, ID : 10.3390/vaccines9050454
Métriques
Partage / Export
Résumé
Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeutic axes: immune checkpoint blockade (ICB), vaccination and adoptive cell transfer (ACT). If originally these therapies mainly focused on exploiting CD8 T cells given their role in the direct elimination of tumor cells, increasing evidence highlights the crucial role CD4 T cells play in the antitumor immune response. Indeed, these cells can profoundly modulate the tumor microenvironment (TME) by secreting different types of cytokine or by directly eliminating cancer cells. In this review, we describe how different CD4 T cell subsets can contribute to tumor immune responses during immunotherapy and the novel high-throughput immune monitoring tools that are expected to facilitate the study of CD4 T cells, at antigen-specific and single cell level, thus accelerating bench-to-bed translational research in cancer.